Rigel Pharmaceuticals, Inc. (RIGL) EPS Estimated At $-0.13

February 12, 2018 - By Marie Mckinney

 Rigel Pharmaceuticals, Inc. (RIGL) EPS Estimated At $ 0.13
Investors sentiment decreased to 1.39 in 2017 Q3. Its down 0.20, from 1.59 in 2017Q2. It dropped, as 7 investors sold Rigel Pharmaceuticals, Inc. shares while 24 reduced holdings. 11 funds opened positions while 32 raised stakes. 104.32 million shares or 0.70% less from 105.05 million shares in 2017Q2 were reported.
The New York-based Engineers Gate Manager L P has invested 0.01% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). 16,029 were accumulated by Amalgamated Savings Bank. Voya Invest Mgmt Limited Liability Co holds 53,661 shares. Hightower Advsr Ltd Llc invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Principal Grp Incorporated invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Tiaa Cref Investment Ltd Liability Corporation owns 305,136 shares. Palo Alto Invsts Lc holds 3.86 million shares. Ascend Ltd Com accumulated 402,522 shares. 198,135 are owned by Citadel Ltd Limited Liability Company. Bnp Paribas Arbitrage holds 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 9,460 shares. 231,736 were reported by Renaissance Limited Liability. Baker Bros Advsrs Ltd Partnership has invested 0.05% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Next Gp reported 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Parametric Assoc Limited Liability holds 24,953 shares or 0% of its portfolio. United Svcs Automobile Association reported 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.13 EPS on March, 6.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.14 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -7.14 % EPS growth. The stock decreased 0.79% or $0.03 during the last trading session, reaching $3.79. About 1.87 million shares traded or 29.80% up from the average. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 4.56% since February 12, 2017 and is uptrending. It has underperformed by 12.14% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 5 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 18 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Buy” rating given on Friday, January 19 by H.C. Wainwright. The company was maintained on Wednesday, June 7 by BMO Capital Markets. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Friday, February 2. BMO Capital Markets maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Tuesday, November 7 with “Buy” rating. The firm has “Hold” rating given on Saturday, August 8 by Zacks. H.C. Wainwright maintained the shares of RIGL in report on Monday, December 11 with “Buy” rating. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, November 6. The firm has “Overweight” rating by Piper Jaffray given on Monday, June 13. The firm has “Buy” rating given on Wednesday, August 31 by H.C. Wainwright. BMO Capital Markets maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Monday, October 2 with “Buy” rating.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $555.20 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: